EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States

Annapoorna S Kini, Gilbert H L Tang, Ricardo Yaryura, George Petrossian, David K Roberts, Ayaz Rahman, Adam Saltzman, Raymond Durkin, James T DeVries, Curtiss Stinis

JACC: Cardiovascular Interventions · 2025-03 · 18 (6) · 785-797

DOI: 10.1016/j.jcin.2024.11.015 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-03. Verfasst von Annapoorna S Kini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Fuster Heart Hospital, Mount Sinai Health System, New York, New York, USA. Electronic address: annapoorna.kini@mountsinai.org. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement, Aortic Valve, Aortic Valve Stenosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Edwards Lifesciences Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Longer term outcomes of transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 Ultra RESILIA (S3UR) valve over its predecessors have not been reported in a national registry. OBJECTIVES: The aim of this study was to compare the 1-year clinical and echocardiographic outcomes of the S3UR with those of the SAPIEN 3 (S3) and SAPIEN 3 Ultra (S3U) in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry. METHODS: From September 2022 to March 2023, patients who underwent native TAVR with the S3UR or the S3 or S3U valve were propensity matched and compared. Predictors of 1-year outcomes were identified. The median follow-up time was 358 days (Q1-Q3: 47-365 days) for the S3UR and 364 days (Q1-Q3: 80-365 days) for the S3 and S3U. RESULTS: A total of 4,598 S3UR patients were propensity matched with 4,598 and 32,536 S3 and S3U patients. At discharge, effective orifice areas were larger in the S3UR group (P < 0.0001). The lower discharge mean gradient in the S3UR group was maintained at 30 days and 1 year (P < 0.0001 for all). At 1 year, all-cause mortality (7.6% vs 9.7%; HR: 0.8; 95% CI: 0.67-0.93; P = 0.004), mild or greater paravalvular leak (PVL) (15.6% vs 18.5%; HR: 0.82; 95% CI: 0.69-0.97; P = 0.02), and life-threatening bleeding (2.0% vs 2.7%; HR: 0.7; 95% CI: 0.54-0.94; P = 0.03) were lower in the S3UR group. S3UR and mild or greater PVL were predictive of 1-year mortality in the overall cohort and in low-risk patients. Valve reintervention remained rare at 1 year (0.6% vs 0.4%; HR: 1.46; 95% CI: 0.77-2.78; P = 0.25). CONCLUSIONS: TAVR with the S3UR is associated with superior 1-year clinical outcomes and lower gradients than its predecessors, with less PVL and low valve reintervention. Longer follow-up will determine the durability of the RESILIA technology in the SAPIEN valve platform.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisTranscatheter Aortic Valve ReplacementAortic ValveAortic Valve StenosisBalloon ValvuloplastyHumansMaleFemaleTreatment OutcomeTime FactorsUnited StatesRegistriesAged, 80 and overProsthesis DesignRisk FactorsAgedRisk AssessmentRetrospective StudiesRecovery of FunctionPostoperative ComplicationsHemodynamics

Stichwörter der Autor:innen

SAPIEN 3 Ultra RESILIAhemodynamic statusmortalityparavalvular leaktranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Mount Sinai Fuster Heart Hospital, Mount Sinai Health System, New York, New York, USA. Electronic address: annapoorna.kini@mountsinai.org.
  • Mount Sinai Fuster Heart Hospital, Mount Sinai Health System, New York, New York, USA. Electronic address: gilbert.tang@mountsinai.org.
  • Sarasota Memorial Hospital, Sarasota, Florida, USA.
  • St. Francis Hospital, Roslyn, New York, USA.
  • Sutter Medical Center, Sacramento, California, USA.
  • Cardiology Associates of East Tennessee, Knoxville, Tennessee, USA.

Förderung

  • Edwards Lifesciences Corporation

Zitieren

APA

Kini, A. S., Tang, G. H. L., Yaryura, R., Petrossian, G., Roberts, D. K., Rahman, A., Saltzman, A., Durkin, R., DeVries, J. T., & Stinis, C. (2025). 1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States. JACC: Cardiovascular Interventions, 18(6), 785-797. https://doi.org/10.1016/j.jcin.2024.11.015

Vancouver

Kini AS, Tang GHL, Yaryura R, Petrossian G, Roberts DK, Rahman A, et al. 1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States. JACC: Cardiovascular Interventions. 2025;18(6):785-797. doi:10.1016/j.jcin.2024.11.015

BibTeX
@article{Kini2025,
  author = {Kini, Annapoorna S and Tang, Gilbert H L and Yaryura, Ricardo and Petrossian, George and Roberts, David K and Rahman, Ayaz and Saltzman, Adam and Durkin, Raymond and DeVries, James T and Stinis, Curtiss},
  title = {1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {6},
  pages = {785--797},
  doi = {10.1016/j.jcin.2024.11.015}
}
Kostenlos starten →